QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
According to the U.S. Food and Drug Administration (FDA), some dietary supplements marketed to treat erectile dysfunction or enhance sexual performance may contain prescription drugs or undisclosed ingredients that could be harmful. These products are typically represented as being “all…
Dr. Catalona’s research group has a long-standing collaboration with deCODE genetics, Inc. In this collaboration, they discovered the first genetic variant associated with prostate cancer susceptibility in 2006, and helped discover and validate a dozen more of the 105 known…
On July 1, 2015, Dr. William Catalona was notified that the National Cancer Institute has awarded a grant of approximately $11 million over 5 years to the Prostate SPORE (Specialized Program of Research Excellence). Dr. Catalona is Principal Investigator of…
Prostate cancer is thought to be the most heritable cancer. Positive family history is consistently associated with a 2- to 4-fold increased risk of the disease. Family and twin studies can demonstrate the importance of genetic and environmental factors in…
The current 10-year relative survival rate for men diagnosed with prostate cancer is 99.7%. This long life expectancy could expose patients to the possibility of developing second primary cancers. In 2011, Dr. Catalona and his research team found that the…
In March, the U.S. Food and Drug Administration (FDA) determined that prescription testosterone therapy is approved only for men who have low testosterone levels caused by certain medical conditions, not men with agerelated low testosterone. “The benefit and safety of…
The winter 2014 issue of QUEST included a Q&A with Dr. Chris Gonzalez, a specialist in reconstructive pelvic surgery. In addition to his surgical responsibilities, Dr. Gonzalez works with the American Urological Association (AUA) as vice chairman of health policy,…
Anew study analyzed 945 patients with prostate cancer managed on active surveillance. Researchers found that men with intermediate-risk cancer had a 3.75 higher chance of dying from prostate cancer than men with low-risk disease within 15 years (11.5% vs. 3.7%)….
There is an increased interest in active surveillance due to concern that men diagnosed with low-risk prostate cancer may be over-treated. However, active surveillance criteria could be improved by identifying factors that place men with low-risk disease at increased risk…
After learning about Movember, Tom Weiland and his wife, Jan, started a Movember movement among their friends and family. They challenged their acquaintances to get involved, grow mustaches and strike up conversations about prostate cancer. At the end of the…
"*" indicates required fields
